Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Business
  • Real Estate
  • Technology
  • Artificial Intelligence
  • Health
ncarol.com

HCPs Anticipate Disruption of Oral T2D Landscape by Division
ncarol.com/10211391

Trending...
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand - 107
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position - 104
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation - 103
RESEARCH TRIANGLE PARK, N.C. - ncarol.com -- A variety of factors are considered when healthcare providers (HCPs) speak upon which type 2 diabetes treatments in the clinical pipeline may be more disruptive and why. According to newly published data by market research from Vivisum Partners, LLC., new arrivals are likely to take some pieces of the current share of oral treatments on market, but it may be enough to cause some dents in multiple treatments due to viable alternatives.

The current market holds a lot of excitement for the oral type 2 diabetes pipeline for drugs that are just as comparable in tolerability, but may differ on other clinical attributes, such as dosing. The most potential risk for a more established treatment will be pipeline products gaining more access.

For example, according to Oral T2D Clinical Pipeline, many HCPs expect oral Insulin's efficacy to be slightly or much better than current oral T2D treatments. In dosing, oral Insulin is believed to be slightly better according to a significant percentage of endocrinologists. Familiarity with HCPs could represent much of the difference in access for patients.

More on ncarol.com
  • Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Designed for Healthcare: How TOLI Is Rethinking Functional Flooring
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth

Despite significant excitement for physicians who are familiar with oral insulin there is significant excitement. There is an overall low level of familiarity with other oral T2D pipeline medications. Only 21% of HCPs are familiar with oral insulin, which is the highest percentage of familiarity among any clinical pipeline treatment.

Vivisum Partners surveyed Endocrinologists and HCPs about each oral type 2 diabetes pipeline therapy. The survey results specify their degree of excitement, "HCPs are evenly split between being excited (48%) vs. ambivalent (48%) towards Sotagliflozin", -said Vivisum's Oral Type 2 Diabetes strategist Patrick Brunell. He adds, this suggests that HCPs are interested in Sotagliflozin, but remain skeptical on how well it will perform in the market." Most Endocrinologists (80%) believe that Sotagliflozin will have about the same level of access as current diabetes medications.

Many of the metrics used in the report show that established treatments may have to get used to sharing larger portions of the Oral T2D marketplace. Relying on brand recognition may or may not be enough. Oral T2D Clinical Pipeline Analysis, https://vivisumpartners.com/reports/new-diabetes-medications-clinical-pipeline-analysis/, published in January 2023 by Vivisum Partners, examines each oral type 2 diabetes drug's strengths and weaknesses across six key clinical attributes:
  • Access
  • Dosing
  • Efficacy
  • Safety
  • Support
  • Tolerability

ABOUT VIVISUM PARTNERS, LLC

More on ncarol.com
  • ICG Homes Breaks Ground on the Triangle's 2027 St. Jude Dream Home
  • KayeDinero Takes Viewers Above Asheville in "Autumn in the Blue Ridge" Aerial Visual
  • PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine

Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.

Contact
Candice Smith
***@vivisumpartners.com


Source: Vivisum Partners, LLC

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Nious Media Expands Gaming Coverage With 2026 Game & Geek Expo Special
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • The Dark Chocolate Nutcracker Marks 15 Years
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • After Nvidia's 14% Drop, Asheville Artist KayeDinero Releases "Nvidia"
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
  • Kitchen Table Economics: An Invitation to Think Differently
  • Gabby Press Earns High Praise From BookLife For Book About the Dangers of Corporate AI
  • Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
  • CB Stuffer Announces Private Sale to Secure Future of Brand Growth
  • The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
  • Apex Wellness Architect Hosts Intimate Tea & Intentions Tea Bar Experience to Close Out the Year
_catLbl0 _catLbl1

Popular on ncarol.com

  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 223
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform - 219
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 196
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 138
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs - 131
  • 450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST) - 127
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration - 125
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers - 120
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA) - 118
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight - 111

Similar on ncarol.com

  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute